您的位置: 首页 > 农业专利 > 详情页

MODULATION D'IMMUNORECEPTEUR DESTINEE AU TRAITEMENT DE CANCER ET D'INFECTIONS VIRALES
专利权人:
THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH
发明人:
SMYTH, MARK
申请号:
CA2921774
公开号:
CA2921774A1
申请日:
2014.08.22
申请国别(地区):
CA
年份:
2015
代理人:
摘要:
A method of reducing or relieving immune inhibition in a mammal includes the step of at least partly inhibiting or reducing CD96 activity in one or more cells of the mammal to thereby relieve immune inhibition and/or enhance or restore immune surveillance in the mammal. Typically, inhibiting or reducing CD96 activity does not include, or depend upon, killing of CD96-expressing cells in the mammal. The method relieves immune inhibition and/or enhances or restores immune surveillance in the mammal to thereby treat or prevent cancer or cancer metastasis and/or a viral infection in the mammal. Also provided is a method of screening, designing, engineering or otherwise producing a CD96-inhibitory agent that relieves immune inhibition and/or enhances or restores immune surveillance in a mammal. Typically, the CD96-inhibitory agent is an antibody or antibody fragment.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充